Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Company Data

Name Mineralys Therapeutics, Inc. - Common Stock

Company Mineralys Therapeutics, Inc.

Symbol MLYS

Website https://mineralystx.com

Primary Exchange

NASDAQ

ISIN US6031701013

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Jon Congleton

Market Capitalization 860 Mio

Country United States of America

Currency USD

Employees 0,1 T

Address 150 N. Radnor Chester Rd., 19087 Radnor

IPO Date 2023-02-10

Ticker Symbols

Name	Symbol
NASDAQ	MLYS

More Shares

Investors who hold Mineralys Therapeutics, Inc. - Common Stock also have the following shares in their portfolio:

AIRBUS FINANCE 16/26 MTN Bond

JPM-E.EQ.JPMEE DAEO Fund

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog